Delcath Systems, Inc. (DCTH) Financial Analysis & Valuation | Quarter Chart
Delcath Systems, Inc. (DCTH)
DCTHPrice: $10.91
Fair Value: 🔒
🔒score
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherap... more
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and m... more
Description
Shares
| Market Cap | $376.63M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Gerard J. Michel |
| IPO Date | 2018-05-03 | CAGR | — |
| Employees | 96 | Website | www.delcath.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 2.39% | Total Yield | 2.39% |
DCTH chart loading...
Fundamentals
Technicals
| Enterprise Value | $293.87M | P/E Ratio | 1091 |
| Forward P/E | -24.1 | PEG Ratio | — |
| P/S Ratio | 4.16 | P/B Ratio | 3.49 |
| P/CF Ratio | 18.56 | P/FCF Ratio | 19.62 |
| EPS | $0.01 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 67.95% | Gross Margin | 0.86% |
| Operating Margin | -0.02% | Profit Margin | 0.01% |
| ROE | 0.01% | ROA | — |
| ROCE | -0.01% | Current Ratio | 11.24 |
| Quick Ratio | 10.33 | Cash Ratio | 3.86 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 14.66 | Piotroski Score | 4 |